Table 2. Single blood routine markers and derives in overall association with the risk of esophageal squamous cell carcinoma mortality.
| Blood parameters | Men | Women | ||
|---|---|---|---|---|
| HR, 95% CI, P | HR, 95% CI, P* | HR, 95% CI, P | HR, 95% CI, P* | |
| Single blood-routine markers | ||||
| Neutrophil | 1.10, 1.03-1.17, 0.005 | 1.09, 1.02-1.16, 0.014 | 1.04, 0.90-1.20, 0.572 | 1.05, 0.92-1.21, 0.465 |
| Lymphocyte | 0.91, 0.85-0.99, 0.019 | 0.92, 0.85-0.99, 0.032 | 0.89, 0.76-1.05, 0.162 | 0.84, 0.72-0.99, 0.037 |
| Monocyte | 0.93, 0.86-1.01, 0.098 | 0.92, 0.85-1.00, 0.053 | 1.00, 0.84-1.19, 0.968 | 1.01, 0.86-1.19, 0.882 |
| Eosinophil | 0.92, 0.84-1.01, 0.072 | 0.91, 0.83-0.99, 0.039 | 0.94, 0.80-1.17, 0.493 | 0.93, 0.78-1.10, 0.399 |
| Basophil | 0.93, 0.84-1.04, 0.210 | 0.94, 0.85-1.05, 0.292 | 1.01, 0.88-1.15, 0.939 | 1.01, 0.87-1.16, 0.936 |
| White blood cell count | 0.99, 0.92-1.06, 0.794 | 0.98, 0.91-1.06, 0.676 | 1.01, 0.86-1.16, 0.994 | 1.01, 0.87-1.17, 0.838 |
| Red blood cell count | 0.99, 0.92-1.06, 0.723 | 1.00, 0.93-1.08, 0.964 | 1.00, 0.86-1.16, 0.994 | 1.00, 0.87-1.16, 0.963 |
| Hemoglobin | 1.07, 0.99-1.15, 0.093 | 1.08, 1.00-1.17, 0.048 | 0.97, 0.83-1.12, 0.662 | 1.00, 0.86-1.17, 0.996 |
| RDW | 0.85, 0.76-0.94, 0.002 | 0.84, 0.75-0.93, 0.001 | 1.02, 0.89-1.18, 0.730 | 1.01, 0.88-1.17, 0.996 |
| Platelet count | 1.23, 1.14-1.32, <0.001 | 1.25, 1.16-1.35, <0.001 | 0.85, 0.74-0.99, 0.040 | 0.90, 0.78-1.05, 0.192 |
| Blood-routine derivates | ||||
| NLR | 1.06, 1.00-1.17, 0.045 | 1.05, 0.99-1.11, 0.119 | 1.06, 0.94-1.20, 0.312 | 1.08, 0.96-1.20, 0.199 |
| PLR | 1.16, 1.09-1.23, <0.001 | 1.15, 1.08-1.22, <0.001 | 0.91, 0.76-1.10, 0.346 | 0.98, 0.84-1.15, 0.844 |
| LMR | 0.94, 0.86-1.02, 0.127 | 0.95, 0.87-1.03, 0.201 | 0.85, 0.66-1.10, 0.224 | 0.78, 0.58-1.05, 0.104 |
| PRR | 1.18, 1.10-1.27, <0.001 | 1.21, 1.13-1.30, <0.001 | 0.86, 0.73-1.01, 0.074 | 0.92, 0.78-1.09, 0.329 |
Notes: RDW, red cell distribution width; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; PRR, platelet count to RDW ratio; HR, hazard ratio; 95% CI, 95% confidence interval. *P was adjusted for age, body mass index, smoking, drinking, family history of cancer, systolic blood pressure, fasting blood glucose, TNM stage, tumor embolus and tumor size.